Aktienanalyse zu Greenwich Lifesciences Inc (GLSI)GLSIGreenwich Lifesciences Inc

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Greenwich Lifesciences Inc (GLSI) appears to be a good buy right now due to its recent EMA approval for the FLAMINGO-01 trial, which could significantly expand its market potential. The current price is $16.46, which is well below its 52-week high of $34.10, indicating potential upside. Additionally, the analyst price target of $69 suggests a substantial upside of approximately 319%. However, the company has reported consistent losses, with a net income of -$5,657,137 in Q1 2026, representing a risk to consider.